

## PRESS RELEASE

---

### **JHL Hosts Clinical Trial Investigator Meeting for JHL1101 Clinical Trials**

**24 April 2017** –Hsinchu, Taiwan and Wuhan, China

JHL Biotech is announcing that it recently hosted an investigator meeting in Frankfurt, Germany for the clinical investigators and study coordinators participating in JHL's ongoing JHL1101 Phase 1 clinical trial in patients with rheumatoid arthritis. The meeting had over 90 representatives from 26 clinical centers in 12 European countries and Taiwan.

Based on feedback from the meetings, JHL is confident in the expeditious completion of the Phase I trial. Investigators are excited to participate in this study and develop an EU-approved rituximab biosimilar for use in global markets, with a focus on the developing world

**End**

#### **Media Contact:**

Gregory Manker  
Phone: +886-909-780-862  
gmanker@jhlbiotech.com

#### **About JHL Biotech**

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit [www.jhlbiotech.com](http://www.jhlbiotech.com).